A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002

NCT04677933 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis

Interventions

DRUG: A: OLP-1002
DRUG: B: OLP-1002
DRUG: C: Placebo

Sponsor

OliPass Australia Pty Ltd

Collaborators

[object Object]